Letrozole Tablets (Generic Femara) - Product information and Uses

Letrozole (Generic Femara) is an oral non steroidal aromatase inhibitor which is used for the treatment of hormonally responsive breast cancer after surgery in postmenopausal women.
Generic Femara is used for the treatment of:

  • Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer
  • Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy
  • First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer


Letrozole Tablets - Availability And Packaging

Letrozole is available as Generic Letrozole (Fertolet Tablets) which is packaged in 2.5 mg tablets.

Letrozole (Generic Femara) - Mechanism of Action

The growth of certain cancers of the breast is stimulated or maintained by estrogens and their treatment is thought to be hormonally responsive(i.e., estrogen and/or progesterone receptor positive or receptor unknown). Treatment of such types of Breast Cancers has included a variety of efforts to decrease estrogen levels or inhibit estrogen effects. Such interventions lead to decreased tumor mass or delayed progression of tumor growth in some women.
The estrogens in postmenopausal women, are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system that inhibits the conversion of androgens to estrogens.

Letrozole For Fertility Treatments

Since 2001 Letrozole (Generic Femara) has been used Off label for ovarian stimulation by fertility doctors since it has fewer side effects than clomifene (Clomid) and less chance of multiple gestation. However a Canadian study presented at the American Society of Reproductive Medicine 2005 Conference has suggested that Letrozole may increase the risk of birth defects.
A follow up study found that letrozole, compared with a control group of clomiphene, had significantly lower congenital malformations and chromosomal abnormalities at an overall rate of 2.4% (1.2% major malformations) compared with clomiphene 4.8% (3.0% major malformations). However certain countries most notably India, have banned the usage of Letrozole for fertility treatments in 2011, due to the potential risks to infants.

Use Of Letrozole In Bodybuilding

Common side effects of some anabolic steroids are bloating due to excess water retention and the formation of Gynecomastia related breast tissue.
Letrozole is preferred by athletes and bodybuilders for use during a steroid cycle to prevent these side effects.

Side Effects of Letrozole Tablets

The most common side effects of Letrozole Tablets occurring in 20% or more of those undergoing therapy were hot flashes, sweating, fatigue, arthralgia (joint pain); flushing, asthenia, edema, arthralgia, headache, dizziness, hypercholesterolemia, sweating increased, bone pain and musculoskeletal disorders.

Letrozole Tablets - Dosage

The recommended dose of Letrozole Tablets is one 2.5 mg tablet administered once a day, with or without meals.

Generic Letrozole Tablets-Contraindications

Generic Letrozole Tablets are contraindicated in patients with known hypersensitivity to Letrozole or any of its inactive ingredients.
Letrozole is contraindicated in women of premenopausal endocrine status during pregnancy and lactation.

Overdosage and Overdose Symptoms of Letrozole Tablets

In reported isolated cases of Letrozole Tablets overdose no serious adverse events were reported. The highest single dose ingested was 62.5 mg or 25 tablets.
As regards treatment, Emesis could be induced if the patient is alert. In general, supportive care and frequent monitoring of vital signs are also appropriate.

Additional Information

Additional Info: Prescribing Information